Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group

Abstract

EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood <i>KMT2A</i>-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.